Department of Radiation Oncology.
Onco Targets Ther. 2013;6:67-74. doi: 10.2147/OTT.S39495. Epub 2013 Feb 7.
To study outcomes of concurrent chemoradiotherapy (CCRT) or radiotherapy (RT) alone followed by radical surgery in patients with local advanced cervical cancer.
A retrospective approach was carried out in 174 Chinese patients with International Federation of Obstetricians and Gynaecologists stage IB2-IIIB cervical carcinoma. A total of 121 patients were treated with CCRT, while the remaining 53 patients received RT alone, and the regimen of chemotherapy was weekly cisplatin (40 mg/m2). Pathological response, overall survival (OS), progression-free survival (PFS), and complications were analyzed.
The median age was 45 years and the mean primary tumor diameter was 4.8 ± 1.0 cm. Pathological complete response (CR) was achieved in 53 patients (30.5%). The CR rate was relatively higher in the CCRT group (31.4% vs 28.3%, P = 0.724), particularly when tumor diameter was less than 5 cm (38.2% vs 30.8%, P = 0.623). With median follow-up of 24 months, patients with CR had improved 3-year OS (100% vs 83.6%, P = 0.018) and 3-year PFS (93.1% vs 83.2%, P = 0.035) compared to patients with residual disease. CCRT was associated with significantly improved 3-year PFS (92.0% vs 76.5%, P = 0.032) compared to RT alone in patients with tumor diameter less than 5 cm. Thirty-seven patients (21.3%) experienced more than grade 2 toxicity, and one patient (0.6%) developed grade 3 uronephrosis. Data thus indicated that pathologic response, tumor size, and lymph-node involvement were highly correlated with clinical outcomes of the local advanced cervical disease.
Preoperative CCRT achieved outcomes superior to RT alone, depending on the pathologic response, tumor size and lymph-node involvement as major prognostic factors.
研究局部晚期宫颈癌患者同步放化疗(CCRT)或单纯放疗(RT)后行根治性手术的治疗效果。
对 174 例国际妇产科联盟妇产科医师协会(FIGO)分期为 IB2-IIIB 期的宫颈癌患者进行回顾性分析。121 例患者接受 CCRT 治疗,53 例患者接受 RT 治疗,化疗方案为每周顺铂(40 mg/m2)。分析病理反应、总生存(OS)、无进展生存(PFS)和并发症。
患者中位年龄为 45 岁,原发肿瘤平均直径为 4.8±1.0 cm。53 例患者(30.5%)获得完全病理缓解(CR)。CCRT 组的 CR 率相对较高(31.4%比 28.3%,P=0.724),特别是肿瘤直径<5 cm 的患者(38.2%比 30.8%,P=0.623)。中位随访 24 个月后,CR 患者 3 年 OS(100%比 83.6%,P=0.018)和 3 年 PFS(93.1%比 83.2%,P=0.035)明显改善。与残留疾病患者相比,CR 患者的预后更好。肿瘤直径<5 cm 的患者中,CCRT 组与 RT 组相比,3 年 PFS 明显改善(92.0%比 76.5%,P=0.032)。37 例(21.3%)患者发生≥2 级毒性,1 例(0.6%)患者发生 3 级尿脓毒症。数据表明,病理反应、肿瘤大小和淋巴结受累与局部晚期宫颈癌的临床结局高度相关。
术前 CCRT 的治疗效果优于 RT 单独治疗,这取决于病理反应、肿瘤大小和淋巴结受累等主要预后因素。